Final visual acuity results in the early treatment for retinopathy of prematurity study
- PMID: 20385926
- PMCID: PMC4162423
- DOI: 10.1001/archophthalmol.2010.72
Final visual acuity results in the early treatment for retinopathy of prematurity study
Erratum in
- Arch Ophthalmol. 2012 Jun;130(6):719
Abstract
Objective: To compare visual acuity at 6 years of age in eyes that received early treatment for high-risk prethreshold retinopathy of prematurity (ROP) with conventionally managed eyes.
Methods: Infants with symmetrical, high-risk prethreshold ROP (n = 317) had one eye randomized to earlier treatment at high-risk prethreshold disease and the other eye managed conventionally, treated if ROP progressed to threshold severity. For asymmetric cases (n = 84), the high-risk prethreshold eye was randomized to either early treatment or conventional management. The main outcome measure was ETDRS visual acuity measured at 6 years of age by masked testers. Retinal structure was assessed as a secondary outcome.
Results: Analysis of all subjects with high-risk prethreshold ROP showed no statistically significant benefit for early treatment (24.3% vs 28.6% [corrected] unfavorable outcome; P = .15). Analysis of 6-year visual acuity results according to the Type 1 and 2 clinical algorithm showed a benefit for Type 1 eyes (25.1% vs 32.8%; P = .02) treated early but not Type 2 eyes (23.6% vs 19.4%; P = .37). Early-treated eyes showed a significantly better structural outcome compared with conventionally managed eyes (8.9% vs 15.2% unfavorable outcome; P < .001), with no greater risk of ocular complications.
Conclusions: Early treatment for Type 1 high-risk prethreshold eyes improved visual acuity outcomes at 6 years of age. Early treatment for Type 2 high-risk prethreshold eyes did not. Application to Clinical Practice Type 1 eyes, not Type 2 eyes, should be treated early. These results are particularly important considering that 52% of Type 2 high-risk prethreshold eyes underwent regression of ROP without requiring treatment. Trial Registration clinicaltrials.gov Identifier: NCT00027222.
Figures





Similar articles
-
Grating visual acuity results in the early treatment for retinopathy of prematurity study.Arch Ophthalmol. 2011 Jul;129(7):840-6. doi: 10.1001/archophthalmol.2011.143. Arch Ophthalmol. 2011. PMID: 21746974 Free PMC article. Clinical Trial.
-
Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.Arch Ophthalmol. 2003 Dec;121(12):1684-94. doi: 10.1001/archopht.121.12.1684. Arch Ophthalmol. 2003. PMID: 14662586 Clinical Trial.
-
Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity.Ophthalmology. 2005 Sep;112(9):1564-8. doi: 10.1016/j.ophtha.2005.03.025. Ophthalmology. 2005. PMID: 16023214 Clinical Trial.
-
Treatment of retinopathy of prematurity.Early Hum Dev. 2008 Feb;84(2):95-9. doi: 10.1016/j.earlhumdev.2007.11.007. Early Hum Dev. 2008. PMID: 18280405 Review.
-
Laser treatment for retinopathy of prematurity.Lasers Med Sci. 2013 Feb;28(2):683-92. doi: 10.1007/s10103-011-1021-z. Epub 2011 Dec 2. Lasers Med Sci. 2013. PMID: 22134790 Review.
Cited by
-
A hybrid method in combining treatment effects from matched and unmatched studies.Stat Med. 2013 Dec 10;32(28):4924-37. doi: 10.1002/sim.5887. Epub 2013 Jul 9. Stat Med. 2013. PMID: 23839782 Free PMC article.
-
Macular findings obtained by spectral domain optical coherence tomography in retinopathy of prematurity.J Ophthalmol. 2014;2014:468653. doi: 10.1155/2014/468653. Epub 2014 Dec 3. J Ophthalmol. 2014. PMID: 25544895 Free PMC article.
-
Association of inflammatory and angiogenic biomarkers in maternal plasma with retinopathy of prematurity in preterm infants.Eye (Lond). 2023 Jun;37(9):1802-1809. doi: 10.1038/s41433-022-02234-9. Epub 2022 Sep 15. Eye (Lond). 2023. PMID: 36109603 Free PMC article.
-
Structural sequelae and refractive outcome 1 year after laser treatment for type 1 prethreshold retinopathy of prematurity in Asian Indian eyes.Indian J Ophthalmol. 2011 Nov-Dec;59(6):423-6. doi: 10.4103/0301-4738.86306. Indian J Ophthalmol. 2011. PMID: 22011484 Free PMC article.
-
Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity.BMJ Open. 2021 Jul 27;11(7):e047003. doi: 10.1136/bmjopen-2020-047003. BMJ Open. 2021. PMID: 34315793 Free PMC article.
References
-
- Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Pediatrics. 1988 May;81(5):697–706. - PubMed
-
- Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988 Apr;106(4):471–479. - PubMed
-
- The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984 Aug;102(8):1130–1134. - PubMed
-
- Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome--structure and function. Arch Ophthalmol. 1990 Oct;108(10):1408–1416. - PubMed
-
- Good WV, Hardy RJ. The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP) Ophthalmology. 2001 Jun;108(6):1013–1014. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical